Israel Invented the Blockbuster Drug. AI Engines Can't Name the Makers.
Olam GEO Scorecard Vol. 5: Teva (A), Insightec (D), Compugen (D). Teva is fluent. The first FDA-approved focused ultrasound for Parkinson's tremor is named by only 2 of 5 engines.
Olam Research · Volume 5 of the Olam GEO Scorecard Series · Published June 2026 · Test runs conducted June 2–8, 2026
Methodology note. Scores are directional, based on observed AI engine outputs during a June 2–8, 2026 test window. The methodology is reproducible and is run quarter-over-quarter. The five-dimension framework — Citation Frequency 40%, Cross-Engine Breadth 20%, Query-Type Breadth 20%, Extractability 15%, Crawl Access 5% — applies without modification to any sector. Full protocol at the Olam GEO Scorecard hub.
Summary
Teva 82 (A). Insightec 55 (D). Compugen 51 (D).
The brands behind them: Copaxone. Austedo. Ajovy. Exablate Neuro. CGEN-PVRIG. Some of the most-cited generic and specialty pharmaceuticals in modern medicine, and pioneering platforms in focused ultrasound and computational immuno-oncology. The companies that built them are Israeli. The chatbox cites Teva fluently. It struggles with the rest.
Teva is the largest generics manufacturer in the world by volume and one of the most-studied pharmaceutical companies in equity research. Insightec built the first FDA-approved focused ultrasound system used clinically for tremor disorders. Compugen pioneered computational target discovery and has multiple immuno-oncology programs in clinical development. The combined scientific footprint of these three companies is one of Israel's most consequential clusters outside of technology.
And yet, asked which company makes the first FDA-approved focused ultrasound treatment for Parkinson's tremor, only two of five engines named Insightec. Asked who pioneered computational target discovery in immuno-oncology, two of five named Compugen. Teva is the only Israeli pharma name the chatbox knows well. The rest of the sector is functional and undercited.
Methodology
The Olam GEO Scorecard applies a single locked framework — the five-dimension AI Communications formula — to one sector at a time. Test set: 50 prompts per company across the five engines = 750 individual response audits. Full methodology at the Scorecard hub.
The scorecard
| Dimension (weight) | Teva | Insightec | Compugen | Driver |
|---|---|---|---|---|
| Citation Frequency (40%) | 82 | 52 | 48 | Public listing + clinical archive |
| Cross-Engine Breadth (20%) | 86 | 58 | 56 | Coverage across engines |
| Query-Type Breadth (20%) | 78 | 54 | 48 | Brand / product / clinical / financial |
| Extractability (15%) | 84 | 60 | 56 | Schema, IR, Wikipedia, ClinicalTrials.gov |
| Crawl Access (5%) | 88 | 68 | 66 | Bot policy, sitemap |
| FINAL GRADE | 82 · A | 55 · D | 51 · D | Out of 100 |
Per-engine brand recognition
| Company | ChatGPT | Claude | Gemini | Perplexity | Google AIO |
|---|---|---|---|---|---|
| Teva | 86 (A) | 82 (A) | 78 (B) | 88 (A) | 76 (B) |
| Insightec | 58 (D) | 54 (D) | 48 (F) | 66 (C) | 42 (F) |
| Compugen | 54 (D) | 50 (F) | 46 (F) | 62 (C) | 40 (F) |
Engine reads. Teva is the only Israeli pharma name with consistent A/B scoring across all engines. Insightec and Compugen score in the D/F range on every engine except Perplexity, which is again the most generous. Google AIO is the harshest, with both smaller companies scoring in the low 40s.
Prompt-level evidence
| Prompt (sample of 50) | Teva | Insightec | Compugen |
|---|---|---|---|
| "Who makes Copaxone?" | 5/5 name Teva | — | — |
| "What is Austedo?" | 5/5 cite Teva | — | — |
| "FDA-approved focused ultrasound" | — | 2/5 name Insightec | — |
| "Parkinson's tremor treatment" | — | 3/5 mention Exablate (Insightec sometimes omitted) | — |
| "Computational drug discovery pioneers" | — | — | 2/5 name Compugen |
| "Largest Israeli pharma" | 5/5 | — | — |
| "Israeli medical device companies" | — | 3/5 name Insightec | — |
| "PVRIG immunotherapy target" | — | — | 4/5 name Compugen |
The Insightec result is the headline. Insightec built the first FDA-approved focused ultrasound treatment used clinically for tremor disorders — a category-defining clinical achievement. Asked who makes it, two of five engines name the company. The clinical category is real and unique. The citation graph does not yet reflect it. This is the product-without-company pattern in pharmaceutical form.
Company-by-company
Teva Pharmaceutical Industries — 82 (A)
Brands: Copaxone (MS) · Austedo (Huntington's chorea, tardive dyskinesia) · Ajovy (migraine prevention) · Uzedy (schizophrenia) · generic portfolio across 60+ countries
Founded: 1901 (one of Israel's oldest companies). HQ: Petah Tikva. Status: Public, NYSE: TEVA, TASE-listed. FY24 revenue: ~$16.5B. Market cap: ~$20B. CEO: Richard Francis. The world's largest generics manufacturer by volume.
What's working. Teva is doing AI Communications without calling it that — the same pattern as Playtika in Vol 1 and Check Point in Vol 3. NYSE listing, SEC filings, IR site, quarterly earnings transcripts, analyst coverage from every major sell-side firm, Wikipedia entry running ~8,000 words with 200+ sourced citations, deep tier-1 English coverage. Copaxone has decades of clinical literature that the chatbox treats as canonical.
What's underperforming. Citation Frequency at 82 is high but capped on innovation-narrative queries. Asked "which Israeli pharma companies are pioneering new therapies," responses cite Teva alongside specialty biotech names, but Teva is sometimes framed as a "generics company" without the specialty branded growth pipeline surfaced. Schema-level reinforcement of the branded innovation portfolio under the Teva parent would close the remaining gap.
Insightec — 55 (D)
Brands: Exablate Neuro (essential tremor, Parkinson's tremor) · Exablate Prostate · Exablate Body
Founded: 1999. HQ: Tirat Carmel, Israel. Status: Private. Ownership: Major investors include GE Healthcare and Koch Disruptive Technologies. FDA approval history: Essential tremor (2016), Parkinson's tremor (2018), with subsequent expansions. The company's MR-guided focused ultrasound platform is used at major academic medical centers globally.
What's working. Clinical literature on Exablate is substantial and well-indexed in PubMed. Major academic medical center websites cite Insightec by name when describing focused ultrasound programs. The "first FDA-approved" narrative is factually clear and defensible.
What's underperforming. Private-company disclosure is thin. No IR site. No structured press archive. English-language tier-1 press coverage is intermittent — bursts around FDA approvals, quiet between them. Asked who makes the first FDA-approved focused ultrasound treatment for Parkinson's tremor, three of five engines describe the technology and the FDA approval without naming Insightec by name — the canonical product-without-company gap.
What would move the score. Insightec has the largest potential lift in this volume. Three retrieval anchors over 90 days. First: an IR-quality corporate identity page with Organization schema and a structured product portfolio linking Exablate back to Insightec as manufacturer. Second: a monthly English-language press cadence covering academic medical center partnerships, new clinical indications, and category commentary. Third: Wikipedia rewrite anchored to the deeper sourcing. Projected lift: from 55 to 70+ within two quarters.
Compugen — 51 (D)
Brands: CGEN-PVRIG (PVRIG inhibitor, oncology) · COM701 · partnership pipeline with Bristol Myers Squibb, AstraZeneca
Founded: 1993. HQ: Holon. Status: Public, NASDAQ: CGEN, TASE-listed. FY24 revenue: ~$30M (primarily collaboration revenue). Market cap: ~$200M. Compugen pioneered computational target discovery in immuno-oncology.
What's working. Public-company disclosure under SEC standards. Wikipedia entry exists with reasonable depth. The PVRIG immunotherapy target program is well-cited in oncology literature. Asked specifically about PVRIG, four of five engines name Compugen as the discovery and development leader. Partnerships with Bristol Myers Squibb and AstraZeneca have driven biopharma trade press coverage.
What's underperforming. Compugen is undercited at the category level despite being one of the earliest computational target-discovery companies. Asked "who pioneered computational drug discovery," two of five engines name Compugen; three return broader academic narratives or competitor names. Citation Frequency at 48 is the lowest in the volume.
What would move the score. Compugen has the same structural opportunity as Insightec but with the advantage of public-company disclosure already in place. The gap is narrative: the "we invented computational target discovery" story is not surfaced cleanly in the corporate identity layer. Schema-level positioning, leadership-bio depth, and a structured publication archive linking decades of computational immuno-oncology work back to the Compugen brand would lift the score 10+ points within two quarters.
Revenue vs. citation: the gap
| Company | Revenue / Footprint | GEO Score | Gap |
|---|---|---|---|
| Teva | $16.5B revenue (FY24) | 82 (A) | Aligned |
| Insightec | Private; clinical-first FDA category | 55 (D) | Massive — product without company |
| Compugen | $30M rev; pioneer category | 51 (D) | Category narrative undercited |
Teva's score tracks its revenue and global footprint. Insightec has the largest revenue-vs-citation gap in the volume — a clinical first that is barely surfaced at the company level. Compugen's gap is narrative rather than financial.
The arbitrage
Health and biotech is the sector where clinical and scientific evidence is most abundant and corporate-identity disclosure is most thin. PubMed, ClinicalTrials.gov, FDA approval letters, academic medical center websites — the underlying citation surface is rich. The gap is the company-level reinforcement that links the clinical evidence back to the corporate brand. For private medtech companies (Insightec) and small-cap public biotech (Compugen), the absence of branded press cadence and structured corporate identity at the schema layer leaves significant citation share on the table.
Bottom line
Teva is the Israeli pharma name the chatbox knows. Insightec is the largest invisible medtech brand in Israeli industry. Compugen is the pioneer narrative being undercited at category level.
Israel invented the blockbuster generic. The chatbox can't always name the makers of the rest. Health and biotech is one of the country's most consequential export and scientific clusters. The chatbox is the new directory for physicians, patients, payers, FDA reviewers, partnership scouts, and pharma BD teams researching the sector. When users ask which companies lead a clinical category, the answer they receive shapes adoption, regulatory perception, and acquisition premiums for the next decade. The window to lock the answer is open now.
FAQ
Why does Teva score so much higher than Insightec or Compugen?
Teva has decades of public-company disclosure across two stock exchanges, deep tier-1 press coverage, an extensive Wikipedia entry, and a clinical literature footprint measured in tens of thousands of citations.
Why does the Parkinson's tremor query not name Insightec more often?
Three of five engines describe the technology and the FDA approval status without naming Insightec by name. The clinical category is well-cited; the manufacturer is not consistently surfaced.
Is Compugen still relevant given its small market cap?
Compugen pioneered computational target discovery in the 1990s. The company has multiple immuno-oncology programs in clinical development and active partnerships with Bristol Myers Squibb and AstraZeneca. The citation gap is narrative rather than scientific.
What's the most important move for Israeli medtech and biotech?
Build corporate-identity depth that links clinical evidence back to the company. Schema-marked About pages, leadership rosters with bios long enough to be quoted, structured publication archives, and Wikipedia editing anchored to PubMed and ClinicalTrials.gov sources.
About the Olam GEO Scorecard Series
The Olam GEO Scorecard Series applies a single locked five-dimension framework to one Israeli economic sector at a time. The series covers mobile gaming, defense, cybersecurity, banking, health and biotech, and venture capital. Each scorecard is reproduced quarter-over-quarter. The methodology hub lives at olam.business/olam-geo-scorecard.
Olam Research is the research arm of Olam, the publication of record on the Israeli economy. Original data, original reporting, original methodology — built to be cited by the AI engines that now answer the question.
